5-phenyloxazole-4-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-phenyloxazole-4-carboxamide
• 英文别名: 5-Phenyl-1,3-oxazole-4-carboxamide
• 化学式: C₁₀H₈N₂O₂
• mdl: MFCD00105451
• 分子量: 188.186
• InChiKey: LXONVEYCDHPQSB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  苯基三甲氧基硅烷 、 5-phenyloxazole-4-carboxamide 在 四丁基氟化铵 、 copper diacetate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以27%的产率得到N,5-diphenyl-1,3-oxazole-4-carboxamide
  参考文献：
  名称：

  α-Nitrogen activating effect in the room temperature copper-promoted N-arylation of heteroarylcarboxamides with phenyl siloxane or p-toluylboronic acid

  摘要：

  Heteroarylcarboxamides containing a-nitrogens undergo copper-promoted N-phenylation with hypervalent phenyl trimethylsiloxane at room temperature, in the absence of base and in air. Arylboronic acid can substitute for phenyl trimethylsiloxane as the organometalloid. The ol-heteroatom chelating effect is in the decreasing order of N>O, S. This discovery opens up the possibility of using other alpha -nitrogen functional groups to direct the N-arylation of peptides and simple amides under conditions as mild as that of amide bond formation. (C) 2001 Dupont Pharmaceutical Company. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)00203-9

文献信息

• OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：Braun Alain

  公开号：US20070149562A1

  公开（公告）日：2007-06-28

  The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

  本发明涉及根据本文所定义的式（I）的化合物，这些化合物是黑色素皮质素受体激动剂，涉及其制备以及在治疗或预防肥胖、糖尿病和可能影响两性的性功能障碍中的治疗用途，治疗心血管疾病，以及抗炎症用途或治疗酒精依赖症。
• Chemical compounds
  申请人：Alcaraz Lilian

  公开号：US20050107428A1

  公开（公告）日：2005-05-19

  The invention provides compounds of formula (I):[Chemical formula should be inserted here. Please see paper copy]wherein: X is CH 2 , O, S(O) 2 or NR 10 ; Y is a bond, CH 2 , NR 35 , CH 2 NH, CH 2 NHC(O), CH(OH), CH(NHCOR 33 ), CH(NHSO 2 R 34 ), CH 2 O or CH 2 S; Z is C(O), or when Y is a bond Z can also be S(O) 2 ; R 1 is optionally substituted aryl, optionally substituted heterocyclyl or C 4-6 cycloalkyl fused to a benzene ring; and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 , R 9 , R 10 , R 32 , R 33 , R 34 and R 35 are as defined herein; are modulators of chemokine (especially CCR3) activity (for use in, for example, treating asthma). The invention also provides a process for making 4-(3,4-dichlorophenoxy)piperidine, which is useful as an intermediate for making certain compounds of the invention.

  该发明提供了式（I）的化合物：[化学式应在此处插入。请参见纸质副本]其中：X为CH2，O，S（O）2或NR10；Y为键，CH2，NR35，CH2NH，CH2NHC（O），CH（OH），CH（NHCOR33），CH（NHSO2R34），CH2O或CH2S；Z为C（O），或当Y为键时，Z也可以是S（O）2；R1是可选择的取代芳基，可选择的取代杂环基或与苯环融合的C4-6环烷基；R2、R3、R4、R5、R6、R7和R8、R9、R10、R32、R33、R34和R35如本文所定义；是趋化因子（特别是CCR3）活性调节剂（例如用于治疗哮喘）。该发明还提供了制备4-（3,4-二氯苯氧基）哌啶的方法，该方法有用于制备该发明的某些化合物的中间体。
• US7709500B2
  申请人：——

  公开号：US7709500B2

  公开（公告）日：2010-05-04
• [EN] PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF<br/>[FR] DÉRIVÉ D'ACIDE PHÉNYLPROPIONIQUE ET SON UTILISATION
  申请人：ASAHI KASEI PHARMA CORP

  公开号：WO2009133831A1

  公开（公告）日：2009-11-05

  　優れた４型ＰＬＡ２阻害活性によりプロスタグランジン及び／又はロイコトリエンの産生抑制作用を有する下記一般式（１）［Ｘはハロゲン原子、置換されていてもよいアルキル基等を示し、Ｙは水素原子又は置換されていてもよいアルキル基を示し、Ｚは水素原子又は置換されていてもよいアルキル基を示す。］で示される化合物又はその塩：
• α-Nitrogen activating effect in the room temperature copper-promoted N-arylation of heteroarylcarboxamides with phenyl siloxane or p-toluylboronic acid
  作者：Patrick Y.S Lam、Sophie Deudon、Elisabeth Hauptman、Charles G Clark

  DOI：10.1016/s0040-4039(01)00203-9

  日期：2001.3

  Heteroarylcarboxamides containing a-nitrogens undergo copper-promoted N-phenylation with hypervalent phenyl trimethylsiloxane at room temperature, in the absence of base and in air. Arylboronic acid can substitute for phenyl trimethylsiloxane as the organometalloid. The ol-heteroatom chelating effect is in the decreasing order of N>O, S. This discovery opens up the possibility of using other alpha -nitrogen functional groups to direct the N-arylation of peptides and simple amides under conditions as mild as that of amide bond formation. (C) 2001 Dupont Pharmaceutical Company. Published by Elsevier Science Ltd. All rights reserved.